An immune-based tool platform for in vivo cell clearance

Life Sci Alliance. 2023 Jun 13;6(8):e202201869. doi: 10.26508/lsa.202201869. Print 2023 Aug.

Abstract

Immunological targeting of pathological cells has been successful in oncology and is expanding to other pathobiological contexts. Here, we present a flexible platform that allows labeling cells of interest with the surface-expressed model antigen ovalbumin (OVA), which can be eliminated via either antigen-specific T cells or newly developed OVA antibodies. We demonstrate that hepatocytes can be effectively targeted by either modality. In contrast, pro-fibrotic fibroblasts associated with pulmonary fibrosis are only eliminated by T cells in initial experiments, which reduced collagen deposition in a fibrosis model. This new experimental platform will facilitate development of immune-based approaches to clear potential pathological cell types in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies*
  • Fibroblasts
  • Hepatocytes
  • Humans
  • Kinetics
  • Pulmonary Fibrosis*

Substances

  • Antibodies